Driven. For a Sustainable Life. Samsung Biologics aspires to lead the industry in protecting our planet for the health of future generations. In our mission to enrich human life while creating enduring and sustainable value, we are investing in practices and technologies to mitigate the risks of climate change in the greater areas we impact. As a global CDMO partner, we recognize the greater impact we can have by working together, and essential to our decarbonization is the cooperation and engagement with our suppliers to accelerate the net zero transition across our supply chains. A blossom of hope We are on a journey to help create a healthier adn sustainable future. Our path to changing the world is never ending. It touches everyone and everything. Together we are Driven. For a Sustainable Life. Driven. For Life. Samsung Biologics ESG Report We're committed to sharing oursustainable progress and goals.Learn more about our sustainability initiatives. Find out more Our InvolvementsWe are committed to global carbon neutrality SMI Sustainable Markets Initiative(SMI) A low-carbon transition engagement led by the British royal family,Samsung Biologics participated as a representative of the global CDMO industryto seek a net-zero supply chain plan Find out more on the SMI website The SMI was launched by HRH The Prince of Wales at the World Economic Forum in 2020. It aims to lead the transition to a sustainable future by convening leaders to bring economic value into alignment with social and environmental sustainability. In 2021, the SMI Health Systems Taskforce was formally launched at COP26 in Glasgow including 13 leaders from across the healthcare system with CEOs/equivalents from: AstraZeneca, GSK, Merck, Roche, Samsung Biologics, Sanofi, Novo Nordisk, the World Health Organization, UNICEF, NHS England, the Sustainable Healthcare Coalition, the Karolinska Institute and the University of Pavia. With its shared ambition to accelerate the delivery of net zero, sustainable healthcare to improve individual, societal and planetary health, the SMI Health Systems Taskforce is committed to delivering action in three priority areas through the establishment of Working Groups: Supply Chains (championed by John Rim, CEO Samsung Biologics). The Supply Chains Working Group is focused on accelerating the net zero transition across health systems supply chains. More specifically, the group aims to work with suppliers to decarbonize upstream product supply chains, with a focus on renewable energy, clean heat, green logistics and common supplier standards. Patient Care Pathways (championed by Paul Hudson, CEO Sanofi). The Patient Care Pathways Working Group focuses on identifying opportunities to deliver net zero patient care while improving health and societal outcomes. The group aims to demonstrate how interventions across the care pathway can drive emissions reductions by decarbonizing care settings, preventing and managing disease progression, and delivering lower-CO2 solutions. Digital Healthcare (championed by Belén Garijo, CEO Merck). The Digital Healthcare Working Group focuses on leveraging digital innovation and technology in order to drive the transition to net zero across health systems. The initial focus of the group is on demonstrating how digital solutions can support reducing emissions across clinical trials while improving patient outcomes and the patient experience. Frontier 1.5D The Frontier 1.5D project is a global collaborative effort to limit temperature rise to 1.5°C above pre-industrial levels.Business leaders from Korea have joined with the British Embassy, Ewha Woman’s University, Financial Supervisory Service, to analyze the financial impact of climate response policies in the effort to address uncertainties associated with climate change and collectively thrive for a net-zero future. As a business sector representative, Samsung Biologics wi

manufacturing partner to ensure a stable supply of life-saving drugs, especially in light of the current pandemic. ISO22301 is especially meaningful given our critical mission to the biopharma industry to providing patients with a stable supply of life-saving therapies under any circumstances OverviewOperating system Content Tab OverviewOperating system Overview Business Continuity Management System (BCMS, ISO22301) Samsung Biologics’ holistic management process that identifies potential threats to an organization and the impacts to business operations from such threats; and provides a framework for building organizational resilience with the capability of an effective response that safeguards the interests of its key stakeholders, reputation, brand and value-creating activities. Purpose of BCMS Samsung Biologics is operating Business Continuity Management System (BCMS) to protect the assets of our company and clients from risks and to stably deliver key products and services to patients. Leadership for BCMS Operation Samsung Biologics hereby pledges to protect the assets of our company and clients from risk and to stably deliver key products and services to patients to comply with our Business Continuity Management policy. We strive to identify and evaluate the risk of disruption to Samsung Biologics' activities in order to be a global leading company by implementing processes to prevent and mitigate the impact of disruption through continuous improvement. We establish a dedicated organization to routinely manage and continually improve suitability, adequacy, and effectiveness throughout the entire whole business continuity management process. We pledge to be a reliable company for our clients and shareholders by actively participating in BCM activities to stably deliver key products and services. Samsung Biologics President & CEOJohn Rim ISO22301 ISO22301 is a comprehensive standard published by the International Organization for Standardization (ISO) that represents the highest level of commitment to business continuity and disaster preparedness. Samsung Biologics became the first Korean pharmaceutical company to achieve ISO22301 certificate in 2018, and has continuously expanded the scope of certification for ensuring systemic BCMS management. Operating system BCMS Steering Group Samsung Biologics has three levels of teams in the response structure. The strategic, tactical, and operational teams in a response structure undertake different activities as follows: Crisis Management Committee Emergency Response - Evacuation- Initial Site response- First aid- Restoration- And others Business Support - Supply Chain- HR- Finance- Quality- And others Manufacturing - Drug Substance- Drug Product- Research- Development- And others Communication Communicate to - Client- Staff- Regulatory Agency- Audit committee- Others BCMO The strategic teams,which focuses on strategic issues that impact the organization's core objectives, products and services, are led by top management.The crisis management team has primary responsibility for addressing any crisis impacting the organization.※ BCMO: Business Continuity Management Office The tactical teams,which manage and coordinate the continuity of the processes required to deliver the impacted products and services and ensure that the resources are allocated appropriately, are led by a team leader. Tactical level plans provide a framework to coordinate strategic goals and decisions with the operational response teams. The operational teams,which focus on the continuity of the activities that contribute to the processes that deliver the prioritized products and services, is led by each functional site matter expert. An operational response establishes the necessary capability required to continue delivering priotised products and services. The strategic teams,which focuses on strateg

manufacturing processes. This support facility, situated strategically at the center of the campus, is poised to play a pivotal role in optimizing production processes and enhancing efficiency, ensuring swift responsiveness to customer needs. Our endeavor to expand our business capability with ADC is also progressing smoothly. Consisting of a 500L conjugation reactor and one purification line, our ADC conjugation facility is scheduled to start operations by the end of the year. Also, through the Samsung Life Science Fund, we have been investing in biotechs around the world with advanced ADC technologies to secure a competitive edge in the ADC field and proactively address market demands. Through these strategic efforts, we aim to build a comprehensive ADC toolbox, thus broadening the scope of services that we can offer to our clients.Growth of CDO with New Platforms Introduction of SelecTailor™, S-Tensify™, and DEVELOPICK™ Ver. 3.0In order to meet the evolving CDO demands of our growing client base, we are committed to expanding new platforms while continuously improving our existing ones. As part of this effort, we introduced our rebranded SelecTailor™ service package and launched our innovative S-Tensify™ platform. Additionally, we unveiled the revamped version 3.0 of our established DEVELOPICK™ platform. S-Tensify™ platform stands out as a high-density cell culture solution, providing nutrient-rich media and effectively eliminating impurities prior to the main cultivation phase. This helps achieve high-concentration cell culture by increasing the inoculation cell density at the stage just before the final cell culture (N-1) by an average of 30 times, leading productivity to be substantially boosted during the final cell culture stage. Meanwhile, SelecTailor™ is designed to support customized biopharmaceutical development, aligning closely with specific customer requirements. This rebranded Customized CMC Solution is expected to not only provide bespoke services based on customers' diversified characteristics and propose development strategies to support successful new drug development, but also enhance our competitive edge in the market. Building upon these strengths and comprehensive service offerings, we are expanding our global reach and remain dedicated to delivering even better results to our existing and potential clients in the future.Continued Investment into New Modalities Investment into Flagship Pioneering Fund VIII to Support New Drug DevelopmentIn July, Samsung Biologics decided to invest USD 52.23 million (KRW 72 billion) in Flagship Pioneering Fund VIII through the Samsung Life Science Fund II, established jointly with Samsung C&T, Samsung Bioepis, and Samsung Venture Investment. Flagship Pioneering is a premier U.S. venture capital firm which manages about USD 14 billion (approx. KRW 19 trillion) in assets and has founded over 100 companies. This Flagship Pioneering Fund VIII, valued at USD 2.6 billion, focuses on platform technologies for new drug development leveraging artificial intelligence (Al). With priority access to and continued investments in innovative biotechs, Samsung Biologics aims to ultimately support and promote significant advancements in drug development.Digital Transformation Client-centered business process optimization through Automation and DigitizationSamsung Biologics is enhancing its CDMO competitiveness by implementing Digital Transformation across all operational areas, from technology transfer to manufacturing processes, aiming to optimize our customer-centric business processes. More specifically, we are trying to maximize efficiency through various activities including implementation of electronic manufacturing batch records (EMBR), use of integrated digital management systems, and adoption of Generative Al. Additionally, we have classified our operations into five categories, each tasked with specific initiatives to drive

manufacturing schedules throughout the year. As a result, we are sustaining full operations in Plant 1 to 3 and successfully ramping up Plant 4, a super plant with 240kL capacity that began its full operation in June 2023. Given the current manufacturing schedule and its rising utilization rate, we anticipate that revenue contribution from Plant 4 will account for approximately 20% of our total DS revenue this year. Furthermore, we are making scheduled progress in the construction of Plant 5 so that it can begin its operations as planned in April 2025, and we are actively engaged in pre-sales activities focused around big pharma clients, similar to our sales approach for Plant 4. As a result of our robust sales execution encompassing all five facilities, we achieved notable milestones including signing contracts with global biopharma companies in the first quarter. Additionally, we have inked a CDO contract with LigaChem Biosciences, formerly LegoChem Biosciences, to collaborate on the development of ADC therapeutics. In March, Samsung Biologics received the 2024 CDMO Leadership Awards presented by Outsourced Pharma and Life Science Connect in recognition of our service and business excellence as a global CDMO company. Based on industry clients' evaluations, we have been awarded in all six performance categories: Quality, Reliability, Capabilities, Expertise, Compatibility, and Service Capabilities. We believe that winning the award for 11 consecutive years demonstrates our dedication to client satisfaction and the strong trust we have built with our clients. For the rest of the year, we will remain committed to accelerating our sales operations by leveraging our outstanding CDMO capabilities and track record, and we look forward to providing you with more positive news regarding contract executions.Portfolio Expansion: Continued investments in laying the groundwork for emerging technologies, ADCAs part of our business portfolio expansion, we have recently increased our investment focus in the ADC area. First of all, we will launch development and manufacturing services for ADC therapeutics, both in clinical and commercial stages, utilizing our standalone, dedicated ADC facility that is expected to be operational within 2024. In addition, we are continuing to invest in promising biotech companies in Korea and throughout the world via the Samsung Life Science Fund, a fund jointly established with Samsung C&T and Samsung Bioepis. Following our investments in companies equipped with ADC technology, such as Araris Biotech in Switzerland and AimedBio in Korea, we also invested in BrickBio, a U.S. based company with ADC and CGT technologies in March. In addition to ADC, we plan to study diverse business opportunities across various areas including AAV. Our aim is to accelerate our platform and business growth by investing in ADC facilities and forming strategic partnerships with biotech companies that have advanced and promising ADC technologies.Biosimilar Business: Preparing for product launches and starting direct salesSamsung Bioepis is also making tremendous strides by consistently expanding the coverage of existing products while simultaneously pursuing various initiatives including the development and release of new pipelines as well as starting directs sales in Korea. In January of this year, Samsung Bioepis received the biologics license application (BLA) approval from the Korean Ministry of Food and Drug Safety (MFDS) for SB12 (Soliris biosimilar), which was launched in several European markets in July of last year, and launched the product on April 1st in Korea, marking a step towards direct sales. Additionally, in February, Samsung Bioepis announced a partnership with Samil Pharmaceutical to co-deliver its SB15 (Eylea biosimilar) to the market after receiving BLA approval from MFDS for SB15 as the first Korean company. With this approval, Samsung Bioepis became the first company in Korea that have obtained BLA app

CEO IR NEWSLETTER Driven. For Life. SAMSUNG BIOLOGICS 2023. 07IR NewsletterDear investors, This is John Rim from Samsung Biologics. First of all, thank you for your continuous interest and support in Samsung Biologics.Key HighlightsFinancial Performance (Quarterly Semi-annual)• Continued strong growth momentum: Rev. +41%, OP +46% * Q2 CAGR over three years ('20~23), consolidated • 2Q Consolidated: Rev. KRW 866B, OP KRW 253B (OPM: 29.3%) (+33% YoY) (+49% YoY) • 2Q Separate: Rev. KRW 637B, OP KRW 254B (OPM: 39.9%) (+27% YoY) (+48% YoY) • 1H Consolidated: Rev. KRW 1,587B, OP KRW 445B (OPM 28.0%) (+36% YOY) (+29% YoY)CDMO• Full operation of P4 240KL with Phase II initiation (Jun) *Blo Campus 1:604KL • Continued orders from Global Pharmas *Pfizer $1,080M, Novartis $391M, US Pharma $113M, EU Pharma $81M • 13 out of top 20 Big Pharmas as clients *Count Before COVID-19:3→ After COVID-19:13 • Cumulative contracts amount of USD 11.3B by Jul. **20: $6.1B → '21:$7.5B '22: $9.58 → 23 2Q: 10.5BBusiness Expansion• NJ sales office launched: Client support in closer proximity (Mar) • ADC investment, commercial operation to begin in '24 • Early operation of P5: Sep '25 → Apr 25 (reduced by 5 months) • Further technology improvement in S-DUAL and mRNA platformBioepis• Lucentis Biosimilar (SB11): Geographic expansion of product launch • Soliris Biosimilar (SB12): EMA approved and launched in EU in Jul. • Humira Biosimilar (SB5): Launched in US in Jul.Samsung Biologics today announced second-quarter 2023 consolidated revenue of KRW 866B and consolidated operating profit of KRW 253B, representing a 33% and 49% increase respectively from the second quarter of 2022. On a separated basis, Samsung Biologics recorded KRW 637B (+ 27% YoY) in revenue and KRW 254B (+48% YoY) in operating profit. We continued to achieve solid YoY revenue growth over 14 consecutive quarters since the COVID outbreak in 2020 and are proud to announce that our business is progressing well in line with the annual revenue guidance of 15-20% growth for 2023, demonstrating our top-notch management execution, successful business performance, and our competitive advantage as a world class CDMO. I am also pleased to share that thanks to our robust sales activities, 13 of the top 20 global pharmas are now Samsung Biologics' clients, resulting in Plants 1, 2, and 3 all running at full capacity and Plant 4's 240kL capacity being fully operational since June 1. Our total cumulative CMO contracts now surpass USD 10B, and we continue to expand partnerships with global pharmas leveraging our CDO capabilities and platforms. Also, our subsidiary Samsung Bioepis has been contributing to top-line growth with the launch of EPYSQLITM (SB12), a biosimilar of Soliris, in the EU market after obtaining the final approval from European Commission, and a biosimilar of Humira named HADLIMATM (SB5), in the US in July. Full operation of Plant 4 dubbed the 'SUPER PLANT', and acceleration of Plant 5's construction timeline by 5 months We began operation of the 60KL portion of Plant 4 last October and unlocked the remaining 180KL portion this June (240KL in total). Our total capacity of 604kL across Bio Campus I is now fully available to support clients at multiple scales and on schedule as we had planned from the very beginning. Our sales activities targeted for P4 have led us to the execution of supply contracts for 16 products with 10 clients, and on-going contract negotiations with 30 clients for 46 products. Based on robust demand from clients, we announced in March the construction of Plant 5 which will be operationally ready by April 2025, about 24 months from groundbreaking and 5 months earlier than the original plan. Successful sales achievements from firm demands We have made significant accomplishments in 2023 by executing long-term supply agreements with multiple